Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy

Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor